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Platinum-containing chemotherapy agents (cisplatin, carboplatin, oxaliplatin) have been approved in the ﬁrst-line setting of
numerous malignancies, such as ovarian, bladder, head and neck, colorectal, and lung cancer. Their extensive use over the last
decade has led to a signiﬁcant increase in the incidence of hypersensitivity reactions, which are deﬁned as unforeseen reactions
whose signs and symptoms cannot be explained by the known toxicity of these drugs. Skin rash, ﬂushing, abdominal cramping,
itchy palms, and back pain are common symptoms. Cardiovascular and respiratory complications can prove fatal. Multiple
pathogenetic mechanisms have been suggested. Hypersensitivity usually appears after multiple infusions, suggesting type I allergic
reactions;however,othertypesofhypersensitivityalsoseemtobeimplicated.Severalmanagementoptionsareavailabletotreating
physicians: discontinuation of chemotherapy, premedication, prolonging of infusion duration, desensitization protocols, and
replacement with a diﬀerent platinum compound after performing skin tests that rule out cross-reactions among platinum agents.
1.Introduction
Platinum-based compounds were ﬁrst synthesized in the
nineteenth century but their clinical use against cancer did
not start until the 1970s. Their activity consists of forming
DNA addicts that inhibit replication and lead to apoptosis
[1, 2]. They have been approved for the treatment of
numerous malignancies, such as ovarian, primary peritoneal
carcinoma, bladder, head and neck, colorectal, pancreatic,
esophageal, gastric, testicular, endometrial, biliary tract, and
lung cancer and mesothelioma [3–15]. Platinum agents are
also eﬀective in pediatric tumors [16, 17]. They are used in
the ﬁrst-line and adjuvant setting but also as retreatment
regimens when there is a long progression-free interval after
treating with the same drugs [18, 19].
Cisplatin[(SP-4-2)-diamminedichloroplatinum]wasthe
ﬁrst of the platinum drugs to be used and is characterized
by neurotoxicity, nephrotoxicity, ototoxicity, and eme-
togenicity [1]. Second-generation platinum derivative
carboplatin [cis-diammine (cyclobutane-1,1-dicarboxylate-
O,O )platinum(II)] diﬀers from cisplatin in the substitution
oftwochloridesbya1,1-cyclobutanedicarboxylategroup.Its
eﬃcacy in the treatment of many of the above malignancies
is equal to that of cisplatin, and its toxicity proﬁle is more
favorable[20].Thus,carboplatinhasoftenbeenusedinplace
of cisplatin [21, 22]. Oxaliplatin [[(1R,2R)-cyclohexane-
1,2-diamine](ethanedioate-O,O )platinum(II)] is a third-
generation platinum compound widely used for the
treatment of metastatic colorectal cancer and a variety of
other malignancies, such as breast cancer, melanoma, non-
Hodgkin lymphoma, and head and neck cancer [23–25].
Common adverse events are myelotoxicity, nausea, vomiting
diarrhea, paresthesia, and dysesthesias [26–28].
Hypersensitivity to a chemotherapeutic agent is deﬁned
as an unforeseen reaction whose signs and symptoms cannot
be explained by the known toxicity of the drug [29]. Indus-
trial complex platinum salts have been reported to cause
hypersensitivity and asthma among reﬁnery workers since2 Metal-Based Drugs
1945 [30]. Hypersensitivity reactions in patients receiving
cisplatinwereﬁrstdescribedinthe1970sinpatientswhohad
been retreated with the drug [31]. Since then, all platinum
agents have been associated with such reactions.
The aim of this paper is to provide recent data con-
cerning hypersensitivity reactions to platinum-containing
chemotherapy agents. We will present the characteristics and
pathogenetic mechanisms of this hypersensitivity, as well as
the basic management options available to date.
2. Incidence
Extensive use of platinum compounds in chemotherapy
during the last decade has led to a signiﬁcant increase
in the incidence of hypersensitivity reactions (Table 1).
Hypersensitivity to carboplatin is rarely observed during the
ﬁrst course of treatment. In fact, the most striking diﬀerence
of carboplatin hypersensitivity, when compared to nonplat-
inum agents, is the fact that most allergic reactions are
reported after the patient has received a signiﬁcant number
of infusions although he has exhibited no hypersensitivity
up until then [32–37]. Half of the reactions observed are
moderate to severe [32]. During the ﬁrst ﬁve cycles, the
overall risk is less than 1% [38]; it rises sharply to 6.5% with
the sixth cycle [39] and has been reported as high as 27% in
patients receiving more than seven cycles of treatment [32,
40, 41]. The overall incidence of carboplatin hypersensitivity
reaches 44% in the third-line retreatment setting [32, 42].
Reactions to carboplatin are usually observed after a median
number of eight infusions [32, 33, 39]. Markman et al. were
the ﬁrst to report that peak incidence of carboplatin reaction
is observed during cycle 2 in the second-line setting [32].
The incidence of cisplatin hypersensitivity exhibits similar
characteristics to those observed with carboplatin. It seems
to range from 5% to 20% and increases with concomitant
radiation [43]. Oxaliplatin-related hypersensitivity reactions
were originally considered less common, but with the
growing use of this drug during the last years, it has been
found that reactions occur at a frequency as high as 18.9%
[44, 45]. However, severe grade 3 or 4 events occur in only
1.6% of patients [46]. These reactions usually develop after
six drug infusions [47]. Severe anaphylaxis is rarely observed
and is mostly described in case reports [48, 49].
To the best of our knowledge, there have still been no
reports of hypersensitivity reactions associated with newer
platinum compounds (i.e., satraplatin, picoplatin). This,
however, may be partly attributed to the fact that for some
of the trials conducted, known hypersensitivity to platinum-
containing compounds was an exclusion criterium. The
prevalence of hypersensitivity to these agents remains to be
explored in larger studies in the future.
3. Risk Factors
Factors predictive of hypersensitivity reactions to platinum
agentsareyettobeclariﬁed.HLAphenotypeandintensityof
exposure inﬂuence the possibility of sensitization in reﬁnery
workers [67]. Prior history of allergy to drugs and various
Table 1: Incidence and severity of hypersensitivity to platinum
agents.
Drug Overall
incidence % Characteristics/Severity
Cisplatin 5−20
(i) Occurs within minutes of
infusion start
(ii) Mostly between 4th−8th
course
(iii) Increases with concomitant
radiation
Carboplatin 1−44
(i) Occurs within minutes or
days from infusion
(ii) less than 1% during cycles
1−5
(iii) 6.5% in cycle 6
(iv) 27% in cycle 7 or more
(v) 44% in 3rd-line retreatment
Half of all reactions observed are
moderate to severe
Oxaliplatin 10−18.9
(i) Occurs within minutes/hours
from infusion
(ii) Mostly after 6th course
(iii) Grade 3-4 in only 1.6%
(iv) Severe anaphylaxis mostly in
case reports
environmental factors are associated with greater risk [68,
69].
In patients receiving carboplatin, the number of prior
platinum treatments and total lifetime exposure is associated
with possibility of hypersensitivity [32, 34, 69–72], but
it is not clear whether lowering individual doses during
retreatment wouldreduce the risk [34]. The interval between
the last infusion of ﬁrst-line chemotherapy and retreatment
is an independent predictive variable [69]. High rate of drug
infusion also seems to be vital [16] whereas selection of
ﬁrst-line and retreatment regimens is not inﬂuential [69].
Most recently, Sugimoto et al. showed that patients with
carboplatin-free interval >13 months was related to a 22-
fold higher risk of hypersensitivity and that a maximum
dose/body of carboplatin >650mg is also an independent
risk factor [40]. Navo et al. observed that carboplatin
hypersensitivity is more frequent in patients with ovarian
cancer [70]. A retrospective study by Lafay-Cousin et al.
in pediatric patients with low-grade glioma concluded that
hypersensitivity reactions occurred signiﬁcantly earlier in
children receiving weekly carboplatin infusions as compared
to children on a monthly schedule. Being a girl was identiﬁed
as a risk factor. The cumulative risk of allergic reactions
increased with the number of infusions, and there was no
evidence of a plateau [17]. It has also been found that the
eosinophilic number and ratio during the previous cycle of
allergy and on the day of an allergic reaction are not helpful
in predicting a hypersensitivity response [73].
The incidence of carboplatin hypersensitivity also seems
to be associated with the type of antineoplastic drugs it isMetal-Based Drugs 3
Table 2: Types of hypersensitivity reactions, their characteristics, and how they are implicated in platinum agent hypersensitivity.
Type of
hypersensitivity Antigen Mediated by Mechanism Involved in platinum
hypersensitivity Symptoms related
I Soluble antigen IgE Mast cell and basophil
degranulation
Carboplatin, Cisplatin,
Oxaliplatin (most)
Early onset symptoms:
itching, chest pain, rash,
anaphylactic reactions
II C e l l -o rm a t r i x -
associated antigen IgG, IgM Phagocyte and NK-cell
activation Oxaliplatin Hemolysis,
thrombocytopenia
III Soluble antigen IgG
Immune complexes,
Phagocyte and NK-cell
activation, complement
ﬁxation
Oxaliplatin Chronic urticaria, joint
pain, proteinuria
IV
Soluble or
cell-associated
antigen
T-cells (TH1, TH2,
Cytotoxic T cells)
Macrophage and
eosinophil activation,
cytotoxicity
Carboplatin, Cisplatin
Delayed reactions, hours
or even days after
infusion
Table 3: Emergency procedures in case of hypersensitivity reactions.
Emergency procedures in case of hypersensitivity reaction to a platinum agent
(1) Interruption of infusion
(2) Administer: i.v. antihistamines (type 1 and 2 histamine receptor antagonists), normal saline infusion, and low-dose corticosteroids
(antihistamines are the ﬁrst to be administered)
(3) In case of a more severe reaction (dyspnoea, laryngospasm, bronchospasm):
(i) oxygen, bronchodilators
(ii) high dose steroids (doses range between 100 and 1000mg of hydrocortisone)
(4) Administer epinephrine in case of hypotension or airway obstruction symptoms
(5) Monitoring until symptoms resolve or for several hours later in case of severe hypersensitivity
combinedwith.Morespeciﬁcally,theCALYPSOtrialshowed
that hypersensitivity reactions occurred more frequently in
patients receiving carboplatin-paclitaxel, as compared to
patients on a combination of carboplatin with pegylated
liposomal doxorubicin (PLD) (18.8% versus 5.6%, resp.)
[74]. Markman et al. also reached the conclusion that
administering PLD with carboplatin substantially reduces
theincidenceofcarboplatin-associatedhypersensitivity[75].
In oxaliplatin regimens, younger age, female sex, and use
of this platinum compound as salvage therapy have recently
been recognized as potential risk factors [46]a so p p o s e dt o
t y p ea n dn u m b e ro fm e t a s t a t i cs i t e s[ 45].
4.Pathophysiology
The exact mechanism of platinum allergy remains unclear
(Table 2) although multiple studies have tried to explain
the underlying pathophysiology. Reactions are thought to
be mainly caused by type I IgE-mediated or type IV T-cell-
mediated hypersensitivity. Nevertheless, the presentation
pattern of these reactions is unpredictable, suggesting that
various immunological and nonimmunological mechanisms
are involved [30].
In type I hypersensitivity reactions, IgE immunoglobulin
causes the degranulation of mast cells and basophils leading
to the nonimmune-mediated histamine and cytokine release
[32, 38, 76, 77]. Early-onset symptoms, such as itching,
chest pain, rash, and anaphylactic reactions are attributed
to this pathway [32]. Hypersensitivity in exposed reﬁnery
workers [30, 39], the need of multiple infusions for sen-
sitization, and positive carboplatin skin tests are in favor
of the above hypersensitivity mechanism but no study has
searched for platinum-speciﬁc IgE [30, 78, 79]. Type IV
hypersensitivitytoplatinumagentsalsoseemstobeinvolved.
Antigens binding to the major histocompatibility complex
activate T cells that have already been sensitized. This
hypersensitivity is associated with the delayed inﬂammatory
reaction presenting hours or even days after the infusion
[32, 80]. Increased production of cytokines, such as tumor
necrosis factor (TNF)-alpha and interleukin (IL)-6, might
be caused by platinum compounds acting as superantigens,
but this has yet to be proven [80, 81]. According to the
latest hypersensitivity models, serotonin is also implicated
in anaphylactic mechanisms, and this could explain the
symptoms of hypertension and bronchospasm [82].
As far as oxaliplatin is concerned, most reactions
seem to be IgE-mediated but type II hypersensitivity is
also implicated with the presentation of hemolysis and
thrombocytopenia [83]. Chronic urticaria, joint pain, and
proteinuria after oxaliplatin regimens have been attributed
to type III allergic reactions [73]. Furthermore, idiosyncratic
reactions characterized by chills, fever, abdominal cramps,
and chest tightness have been described during the infusion
[81, 84, 85].
The development of carboplatin hypersensitivity after a
median number of eight therapy courses has been attributed4 Metal-Based Drugs
Table 4: Main desensitization protocols for carboplatin-cisplatin hypersensitivity. We observe that all protocols deliver the platinum agent
at escalating concentrations and administer premedication.
Patients Premedication dose
route Steps Duration Success rate
Abe et al.
(2010) [50]
3( c a r b o p l a t i n
replaced by cisplatin
after
desensitization)
Dexamethasone
20mg, promethazine
50mg, ranitidine
50mg
From 1:1000 to 1:10
on 1st day (in 3 steps),
from1:10to1:1on
2nd day (in 2 steps)
2d a y s( 3h o u r so n1 s t
day, 9 hours on 2nd day) 100%
Gomez et al.
(2009) [51] 7
Dexamethasone at
least 20mg iv 30,
clemastine 2mg iv
From 1:1000 to 1:1 in
4s t e p s 2 hours 71%
Hesterberg
et al. (2009)
[52]
30
Fexofenadine 180mg
po and/or
desloratadine 5mg po
BID, Dexamethasone
10mg po
From 1:100 to 1:1 (in
8−10 steps) 11 hours 99%
Castells
et al. (2008)
[53]
63 (60
hypersensitive to
carboplatin, 3 to
cisplatin)
Diphenhydramine or
hydroxyzine 25mg po
or iv, famotidine
20mg iv or ranitidine
50mg iv, lorazepam
(0.5-1mg po or iv as
needed for anxiety)
From1:100to1:1in
12 steps 5.8 hours
Severe reactions
in 6% of courses
(full target dose
with treatment)
Conﬁno-
Cohen et al.
(2005) [54]
23
Dexamethasone
8−12mg iv,
ondansetron iv
From 1:1000 to 1:1 in
4s t e p s 6 hours 86.9%
Lee et al.
(2005) [55]
31 (1st
desensitization in
intensive care
unit—subsequent as
outpatient)
Diphenhydramine
25mg iv, famotidine
20mg iv Lorazepam
1mg (as needed for
anxiety)
From1:100to1:1in
12 steps(higher
concentrations as
outpatient)
5.8 hours (inpatient) 3.8
hours (outpatient)
85% courses
without
symptoms (full
target dose with
treatment)
Markman
et al. (2004)
[56]
5 (desensitization
and retreatment
with carboplatin or
cisplatin)
Zileuton 600mg po
Q I D( 5d a y s ) ,
montelukast sodium
10mg po QD (5
days), indomethacin
5 0m gp oT I D( 1d a y ) ,
albuterol sulfate 8 mg
po BID (1 day),
famotidine 20mg iv,
dexamethasone 20mg
iv, diphenhydramine
50mg iv
From 1:1000 to 1:1 in
4s t e p s 90 minutes 80%
Jones et al.
(2003) [57]
5( c a r b o p l a t i n
replaced by cisplatin
after
desensitization)
Dexamethasone
20mg po (4 days ),
diphenhydramine
50mg po (4 days),
ranitidine 50mg iv,
dexamethasone 20mg
iv, ondansetron 8mg
iv
From 1:1000 to 1:1 in
4s t e p s 2 hours 60%
Rose et al.
(2003) [33] 33
Dexamethasone
20mg po or iv 6hours
before,
Dexamethasone
20mg iv and
diphenhydramine
50mg iv 30 minutes
before
From 1:1000 to 1:1 in
4s t e p s 16.5 hours 79%
BID: twice a day, iv: intravenously, po: by mouth, QD: once a day, QID: four times a day, TID: three times a day.Metal-Based Drugs 5
Table 5: Castells’ 12-step desensitization protocol.
Step Solution Rate
(mL/h)
Time (in
minutes)
Volume
infused
per step
(mL)
1
100-fold dilution of ﬁnal
target concentration
2.0 15 0.50
2 5.0 15 1.25
3 10.0 15 2.50
4 20.0 15 5.00
5
10-fold dilution of ﬁnal
target concentration
5.0 15 1.25
6 10.0 15 2.50
7 20.0 15 5.00
8 40.0 15 10.00
9 Concentration was
calculated by subtracting
the cumulative dose
administered in steps 1−8
from the total target dose
10.0 15 2.50
10 20.0 15 5.00
11 40.0 15 10.00
12 75.0
prolonged
to
complete
target dose
232.50
to the fact that the patient is exposed to very low concentra-
tions of “free” platinum during each infusion. The threshold
forthemanifestationofareactionisconsideredtobelowered
with each treatment [68, 86]. According to Markman et
al., the patient is sensitized during the ﬁrst-line treatment
(6 courses), and retreatment with the same drug provides
the additional immunological stimulation necessary for a
reaction during infusion number 8 [32]. Novel studies have
suggested that hypersensitivity to platinum agents is not only
caused by their common platinum component but also by
their diﬀerent structures and biological targets. According
to molecular analyses, cisplatin, carboplatin, and oxaliplatin
aﬀect various genes, many of which regulate cell cycle and
signal transduction [87, 88].
5.Symptoms
Platinum hypersensitivity symptoms may develop acutely
during infusion or within minutes, hours, or days after the
infusion [32]. A mild rash may be the ﬁrst manifestation
of hypersensitivity, and this will be followed by more
severe reactions in 50% of patients. Symptoms of mild
hypersensitivity include skin rash, urticaria, ﬂushing, palmar
itching, burning, edema of the face and hands, abdominal
cramping and diarrhea, back pain, and pruritus. They
usually resolve quickly with antihistamines and steroids.
More severe reactions manifest with bronchospasm, tachy-
cardia, hypotension or hypertension, seizures, and chest
pain. Systemic anaphylaxis may be life-threatening [30, 32,
34, 39, 76, 89, 90].
In oxaliplatin-based regimens, dysesthesia with laryngeal
spasm may occur during, immediately after, or even hours
after the drug administration [86, 91–93]. Respiratory
problems may be more severe than initially estimated in
many cases, as hypoxemia in oxaliplatin-related reactions is
often found with no symptoms of dyspnoea [73].
6.TreatmentStrategies
It is recommended that treating physicians inform patients
receiving platinum agents of the risks of hypersensitivity,
especiallyaftermultipleinfusions.Itisimportantforpatients
to be alert and appropriately educated, so that symptoms
are promptly recognized. Administration of platinum drugs
should take place in a medical setting with all necessary
equipment, and the staﬀ should be experienced in treating
hypersensitivity reactions. When a reaction occurs, the
infusion should be immediately stopped, and normal saline,
intravenous antihistamines, and low-dose corticosteroids
should be administered (Table 3). The main dilemma is
whether the platinum-based regimen should be completely
discontinued in future infusions. When the reaction is life-
threatening, all platinum compounds are usually excluded
from future treatment options. In case of mild-to-moderate
hypersensitivity reactions, there is a range of management
options [34].
6.1. Infusion Rate and Premedication. Lowering of infusion
rate and use of premedication with corticosteroids and
antagonists of histamine receptors have allowed successful
readministration of the platinum agent in some case;
however there is great risk of recurrence. Some studies
actually suggest that in carboplatin patients who still have
not exhibited hypersensitivity after a total of 8 infusions,
premedication should be given as precaution, and the
administration rate should be signiﬁcantly decreased in
order to lower the future risk [34]. A retrospective study
was most recently conducted by O’Ceabhaill et al. and
included 777 patients with relapsed ovarian, fallopian tube,
or primary peritoneal cancer retreated with carboplatin. The
data showed that an incrementally increasing, 3-hour infu-
sion during carboplatin retreatment, along with appropriate
premedication, may reduce hypersensitivity reactions, when
compared to the standard 30-minute infusion [34].
6.2. Desensitization Protocols. Various desensitization pro-
tocols have been successfully implemented in order to re-
administer the same platinum agent, especially in cases
where the patient seems to have been beneﬁted by the drug
(Table 4). Protocols are based on gradual reintroduction of
small amounts of drug antigen while escalating to the full
dose, on prolonged infusion and premedication. Successful
desensitization protocols are usually time-consuming [30,
32, 33, 38, 50, 53–57, 89–91]. Prolonged desensitization
is probably more tolerable when considering the changes
caused in the extracellular ﬂuid drug concentration rate
[94]. However, rapid protocols that develop desensitization
within 4−8 hours have also been attempted [78]. A recent
trial by Castells et al. included 413 cases and reported a 12-
step intravenous and intraperitoneal rapid desensitization
protocolthatcanbeappliedinawiderangeofchemotherapy
agents (Table 5). The population consisted predominantly6 Metal-Based Drugs
Table 6: Published desensitization protocols for oxaliplatin hypersensitivity. We observe that almost all protocols deliver the platinum agent
at escalating concentrations and administer premedication.
Patients Premedication-Dose-Route Steps Duration Success rate
Syrigou et al.
(2009) [58] 3N o n e From 1:100000 to
1:1in13steps 8 hours 100%
Castells et al.
(2008) [53] 1
Diphenhydramine or hydroxyzine
25mg po or iv, famotidine 20mg iv or
ranitidine 50mg iv, lorazepam
(0.5−1mg po or iv as needed for
anxiety)
From1:100to1:1in
12 steps 5.8 hours 100%
Nozawa et al.
(2008) [59] 1
Famotidine 20mg iv QD,
Dexamethasone 20mg iv QD,
diphenhydramine 50mg po QID,
domperidone 10mg po QID,
hydrocortisone 100mg iv QD,
granistron 3mg iv QD
From 1:10000 to 1:1
in 5 steps 8 hours 100%
Wrzesinski et
al. (2007)
[60]
1
Famotidine 20mg iv BID,
Dexamethasone 20mg iv QD,
diphenhydramine 50mg iv QD,
magnesium sulfate 1g iv BID, calcium
gluconate 1g iv BID, ondasetron 8mg
iv BID
From 1:10000 to 1:1
in 5 steps 6 hours 100%
Edmondson
et al. (2007)
[61]
1N o n e From 1:10000 to 1:2
in 12 steps 205 minutes 100%
Herrero et al.
(2006)[62] 5N o n e
From 0.003 to
0.75mg/min in
several steps
5-6 hours 100%
Mis et al.
(2005) [63] 1
Dexamethasone 20mg iv,
prednisolone 20mg po QID,
diphenhydramine 50mg iv, cimetidine
300mg iv, magnesium sulfate 1g iv,
calcium gluconate 1g iv, ondasetron
8mgiv
From 1:10000 to 1:1
in 5 steps 8 hours 100%
Lim et al.
(2004) [64] 1
Diphenhydramine 50mg po QID and
30mg iv QD, metoclopramide 9mg iv
QD
Continuous ﬁxed rate 24 hours 100%
Gammon et
al. (2004)
[65]
1 Dexamethasone iv, hydrocortisone
100mg iv, diphenhydramine iv
From 1:10000 to 1:1
in 5 steps 8 hours 100%
Sch¨ ull et al.
(2001) [66] 1 Dexamethasone iv (high dose),
antihistamine iv, ondasetron 8mg iv Continuous ﬁxed rate 48 hours 100%
BID: twice a day, iv: intravenously, po: by mouth, QD: once a day, QID: four times a day.
of women with ovarian cancer, therefore, its eﬃcacy, and
safety remain to be proven in other populations as well
[53]. It should be noted that there have also been reports of
successful desensitization in children [95]. Risks and beneﬁts
of desensitization protocols must be carefully weighed, and
patients should be informed of the danger as there is still
risk of anaphylaxis, or even death during the platinum
rechallenge [89, 90, 96].
6.3. Substituting with a Diﬀerent Platinum Agent. Substi-
tuting one platinum agent with another without additional
desensitization is another management option available in
case of hypersensitivity [32, 97–100]. Successful replacement
of carboplatin by cisplatin has been demonstrated in women
with gynecological malignancies [57, 101] but the true
incidence of cross-reactivity between platinum salts is not
yet known. The possibility of developing a reaction to
the substituting platinum agent may be as high as 25%
[101], and cases of fatal cisplatin reactions after carboplatin
hypersensitivity have been reported [89, 102].
6.4. Skin Testing. Skin testing has been used in an eﬀort
to predict hypersensitivity reactions in patients about to be
re-administered platinum salts [30, 103]. Markman et al.
reported that skin tests had been positive in six of seven
patients who later developed anaphylaxis during carboplatin
readministration[103],thus,suggestingthathypersensitivity
reactions can be predicted. Zanotti et al. [30] used similarMetal-Based Drugs 7
skin testing to identify patients at risk and reported a 99%
negative predictive value. It seems that skin tests are positive
in more than 80% of reactive patients and that when they
are negative, the risk of hypersensitivity reactions is reduced
sevenfold or even eliminated [30, 78]. Therefore, it has been
recommended that skin testing is performed in every patient
before administration of the eighth dose.
Skin testing can prove helpful in an eﬀort to rule out
cross-reactions when one platinum salt is substituted by
another [100, 104, 105]. More speciﬁcally, patients testing
negative for cross-reaction in skin tests seem to be able
to safely continue chemotherapy with a diﬀerent platinum
compound. Platinum-based treatment is safely administered
without need of pretreatment, and this can prove useful in
patients with contraindications to prolonged corticosteroid
exposure [102]. It should be noted that patients with positive
skin tests were also more likely to exhibit hypersensitivity
reactions during desensitization protocols as compared to
patients with negative skin tests [52].
The usefulness of skin testing in everyday clinical setting
remains an issue of controversy. It does not seem practical to
use it as a routine screening test in all patients retreated. It
requires prior experience and use of a control. Furthermore,
hypersensitivity reactions might still occur even in case of
negative skin tests. However, many experts support that
skin testing can be extremely helpful when the expected
prevalenceofhypersensitivityishigh.Thereisneedforlarger
studies in the future in order to clarify the role of skin testing
and to establish proper guidelines.
As far as oxaliplatin hypersensitivity is concerned, pre-
treatment regimens with corticosteroids, antihistamines,
and extension of administration time have been somewhat
successful but their reliability has not yet been proven
[63, 84, 91, 106–108]. Brandi et al. [107]a n dS u ie ta l .
[109] reintroduced oxaliplatin in patients having received
prophylactic Dexamethasone and antihistamines but hyper-
sensitivity recurred in a signiﬁcant number of patients.
Similar data were reported by two Japanese retrospective
studies [45, 73]. Oxaliplatin desensitization protocols have
been reported in a very small number of patients [15,
56, 58–66, 110] with the total infusion time ranging from
2t o2 4h o u r s( Table 6). Better response rates and longer
time-to-progression were observed with chronomodulated
(10am−10pm) oxaliplatin infusion [111]. Wrzensinski et
al. added magnesium sulfate and calcium gluconate to
a previously published protocol and suggested that this
may increase the success rate of desensitization [60]. Skin
testing for oxaliplatin is 75% to 80% accurate according to
Meyer et al. [110] and Garuﬁ et al. [112].
7. Conclusions
Platinum-inducedhypersensitivityreactionsareapotentially
fatal complication that occurs at a rising incidence rate
due to the growing use of these agents in chemotherapy.
The clinical symptoms range from a mild rash to severe
anaphylaxis, and multiple types of hypersensitivity seem
to be implicated. Doctors as well as patients should be
appropriately educated to promptly recognize symptoms. In
case of severe anaphylactic reactions, platinum-based treat-
ment is usually completely discontinued. In more moderate
reactions, patients can be rechallenged with infusion rate
reduction and premedication, by following a desensitization
protocol or by receiving a diﬀerent platinum chemotherapy
agent. Skin testing can help rule out the possibility of cross-
reaction between platinum-based compounds rendering
continuation of eﬀective platinum-based chemotherapy safe.
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